Rallybio Corporation

RLYB | NASDAQ

Price Alert Chart Builder DCF Calculator

$16.90

-$0.03 (-0.18%)

Sep 22, 2026, 1:58 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.18%

(1D)

Rating

Updated: Aug 13, 2026

Fundamentals Average

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $89.69M

1D Range

16.72 17.12

52W Range

3.67 17.57

Valuation (TTM)

PE 2.17

PB 0.95

EV/EBITDA -0.11

Valuation (NTM)

Forward PE N/A

Forward PEG 0.02

Price Target N/A

Cash Flow

FCF Yield 29.3%

SBC Adj. FCF Yield 26.1%

SBC Impact -10.8%

Margins

Gross Margin -1107.6%

Operating Margin -3672.3%

FCF Margin 4077.4%

Growth (CAGR)

Revenue 3Y | 5Y 30.5% | 60.2%

Dil EPS 3Y | 5Y 236.3% | 59.9%

FCF 3Y | 5Y 173.0% | 47.1%

Returns

ROA 46.5%

ROE 68.6%

ROIC -24.4%

Financial Health

Net Cash

$92.85M

Current Ratio 27.26

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most adva...

Sector Healthcare

Industry Biotechnology

Employees 7

IPO Date Jul 28, 2021

Website www.rallybio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞